Patients, platforms, Lilly, and Nvidia. Abridge’s first keynote had it all.
There were enough major announcements to fill an entire issue of DHW, so here’s the abridged version of the top stories to come out of NYC.
The new platform stole the show. Abridge unveiled “the first AI-native clinician intelligence platform” organized around patients, built for clinicians, and designed to help health systems.
- Before the visit: The platform surfaces care gaps and relevant clinical context so clinicians can address what matters during the visit instead of discovering it in retrospective chart reviews.
- During the visit: Abridge suggests discussion topics while delivering evidence-based answers to clinical questions from a growing content library that includes new specialty-focused partners like AAFP, AAN, ADA, and ASCO.
- After the visit: Abridge generates documentation, flowsheets, patient summaries, orders, and billing codes (soon to be fine-tuned through a new partnership with AHIMA).
“The base unit of healthcare is a clinician caring for a patient.” As Abridge pushes into new models of care delivery, its platform will provide the connective tissue between the clinical workflows where care actually gets delivered and outside orgs like payers or life sciences firms.
- The keynote highlighted some key examples: Cigna was on stage discussing how embedding AI in clinical workflows has the potential to unlock real-time claims adjudication, and Aetna shared how it could help realize the promise of VBC.
- More than 300 health systems are already live, including a just-announced rollout at Northwestern Medicine.
Eli Lilly is buying into the vision. The pharma giant made a strategic investment in Abridge’s next chapter, and even though the keynote was light on details, the move started to add up after seeing one of the new capabilities coming to the platform: clinical trial screening.
- By comparing clinical guidance with patient-provider conversations in real-time, Abridge can surface relevant trials directly in the encounter – the moment it matters most.
- They didn’t mention a check size, but big opportunities attract big investments, and identifying candidates while initiating screening at the point of care sounds huge.
Last, but certainly not least, Nvidia. Abridge is teaming up with Nvidia to develop a first-of-its-kind foundation model for clinical conversations that’s trained, shaped, and evaluated against real-world conditions.
- We’ll have to wait until later this year to see it in action, but a little pre-, mid-, and post-training magic with Abridge’s de-identified clinical data will apparently help make it the first model that can “reason clinically from its foundation.”
The Takeaway
If the keynote made one thing crystal clear, it’s that Abridge’s platform doesn’t revolve around AI documentation. It revolves around patients, and every new feature is purpose-built to prove it.
